Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phleum pratense extract is a standardized allergenic preparation derived from the pollen of Timothy grass (Phleum pratense). It is primarily used for allergen-specific immunotherapy to treat and prevent symptoms of allergic rhinitis (hay fever) and related respiratory allergies caused by grass pollens. The mechanism of action involves desensitizing the immune system to specific allergens through repeated exposure to small amounts of the allergen. This leads to modulation of T and B cell responses and increased production of protective IgG4 antibodies that block allergic reactions[1][4][5]. Phleum pratense extract can be administered sublingually (under the tongue) or via subcutaneous injection. Prescription products such as Grazax (sublingual tablet), Alutard SQ (injectable), and Grastek are approved for use in allergy immunotherapy[1][8]. The main indication is for patients with confirmed sensitivity to Timothy grass pollen who experience seasonal hay fever with or without conjunctivitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phleum pratense extract.